M Wadelius

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenomics J 4:40-8. 2004
  2. ncbi request reprint Pharmacogenetics of warfarin: current status and future challenges
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
    Pharmacogenomics J 7:99-111. 2007
  3. ncbi request reprint A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy
    A K Hamberg
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 81:529-38. 2007
  4. pmc Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
    B Glimelius
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Pharmacogenomics J 11:61-71. 2011
  5. pmc Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing
    Mia Wadelius
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala University Hospital, Entrance 61, SE 751 85 Uppsala, Sweden
    Genome Med 3:78. 2011
  6. ncbi request reprint Common VKORC1 and GGCX polymorphisms associated with warfarin dose
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenomics J 5:262-70. 2005
  7. ncbi request reprint Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer
    M Wadelius
    Department of Medical Sciences, Unit of Clinical Genetics, University Hospital, Uppsala, Sweden
    Pharmacogenetics 9:333-40. 1999
  8. doi request reprint A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age
    A K Hamberg
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
    Clin Pharmacol Ther 87:727-34. 2010
  9. ncbi request reprint Prostate cancer associated with CYP17 genotype
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenetics 9:635-9. 1999
  10. ncbi request reprint Induction of CYP2D6 in pregnancy
    M Wadelius
    Department of Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Clin Pharmacol Ther 62:400-7. 1997

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenomics J 4:40-8. 2004
    ....
  2. ncbi request reprint Pharmacogenetics of warfarin: current status and future challenges
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
    Pharmacogenomics J 7:99-111. 2007
    ..Implementation of pre-prescription genotyping and individualized warfarin therapy represents an opportunity to minimize the risk of haemorrhage without compromising effectiveness...
  3. ncbi request reprint A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy
    A K Hamberg
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 81:529-38. 2007
    ..It is important to account for CYP2C9 and VKORC1 genotypes and age to improve a priori and a posteriori individualization of warfarin therapy...
  4. pmc Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
    B Glimelius
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Pharmacogenomics J 11:61-71. 2011
    ..Carriers of the ABCB1 1236T-2677T-3435T haplotype responded to treatment less frequently (43 vs 67%, P=0.027), and survived shorter time, OR=1.56 (95% CI=1.01-2.45)...
  5. pmc Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing
    Mia Wadelius
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala University Hospital, Entrance 61, SE 751 85 Uppsala, Sweden
    Genome Med 3:78. 2011
    ..A report on the 9th Annual Cold Spring Harbor/Wellcome Trust meeting 'Pharmacogenomics and Personalized Medicine', Hinxton, Cambridge, UK, 29 September to 2 October 2011...
  6. ncbi request reprint Common VKORC1 and GGCX polymorphisms associated with warfarin dose
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenomics J 5:262-70. 2005
    ..Genotype-based dose predictions may in future enable personalised drug treatment from the start of warfarin therapy...
  7. ncbi request reprint Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer
    M Wadelius
    Department of Medical Sciences, Unit of Clinical Genetics, University Hospital, Uppsala, Sweden
    Pharmacogenetics 9:333-40. 1999
    ..19 (95% confidence interval 0.41; 3.42), P = 0.75. Smoking is not a known risk factor for prostate cancer, and the association between CYP2D6 poor metabolism and prostate cancer in Danish smokers may have arisen by chance...
  8. doi request reprint A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age
    A K Hamberg
    Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
    Clin Pharmacol Ther 87:727-34. 2010
    ..This reformulated K-PD model decreases dependence on PK data and enables robust assessment of INR response and dose predictions, even in individuals with rare genotype combinations...
  9. ncbi request reprint Prostate cancer associated with CYP17 genotype
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenetics 9:635-9. 1999
    ..If verified, this genotype is likely to convey a larger risk on a population basis, than the rare hereditary prostate cancer genes do...
  10. ncbi request reprint Induction of CYP2D6 in pregnancy
    M Wadelius
    Department of Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Clin Pharmacol Ther 62:400-7. 1997
    ..Both studies indicate an increase in CYP2D6 activity during pregnancy, which may be caused by an induction of the CYP2D6 enzyme...
  11. ncbi request reprint Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis
    M Wadelius
    Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden
    Pharmacogenetics 10:35-41. 2000
    ..Instead, selection bias was suspected since more slow acetylators may have discontinued sulphasalazine therapy because of drug-intolerance...
  12. doi request reprint Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients
    E Hatch
    J Thromb Haemost 6:1038-40. 2008
  13. doi request reprint Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta
    M Rahi
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
    Hum Exp Toxicol 27:65-71. 2008
    ..Absence of a normally functioning P-gp can lead to a highly increased tissue penetration of a number of clinically important drugs...